Clever Culture Systems (CC5) Q4 2024 earnings summary

Executive summary

• Sales strategy targets large global pharmaceutical manufacturers, with APASⓇ instruments placed for evaluation at two major companies and AstraZeneca's final onsite validation underway.

• Five APAS Independence instruments sold to AstraZeneca, with installation planned over six months.

• Early exercise of ~$1 million in options by top shareholders, including board members, strengthened the cash position.

• Consolidated cash balance at 30 June 2024 was $2.4 million, with short-term receivables exceeding $1.7 million.

• APAS technology validated by AstraZeneca, with potential for further orders after phase one rollout.

Financial highlights

• Net cash outflows of AUD 0.1 million for the quarter ended 30 June 2024.

• Operating and investing outflows totaled AUD 1.2 million, offset by AUD 1.1 million in financing inflows.

• Cash and cash equivalents at quarter end were $2.35 million.

• Receipts from customers were $214,000 for the quarter, with $1,079,000 year-to-date.

• Expected inflows next quarter include AUD 0.8 million from debtors and AUD 1 million from R&D Tax Incentive.

Outlook and guidance

• Eight APAS instruments to be shipped in H1 FY2025, the largest volume to date.

• Focus on customer experience, sales execution, and market expansion, targeting a $2.8 billion addressable market.

• Pipeline includes ongoing customer validations and product evaluations, with anticipated sales and grant receipts in the next two quarters.

• Continued support for AstraZeneca and NovaCina through validation and installation.

• Company expects to continue operations and meet business objectives, supported by expected receipts and potential sales.